It is my understanding that they can buy those only for .08 which goes to the company, but I do not know if the stock must reach and hold a trigger price for a certain time first, which is common.
If the stock is worth .08, and all the warrants are converted at .08, the company swaps new shares for .08, when the existing shares are worth .08, where is the dilution? It improves the compnaies cash position and it future potential based on the improved cash.
The next question is what will the merger cost us!!!!! My guess is the merger will cost us about .01-.02 a share in real cost (stock dilution) wise for what we will get. I expect the creditors are going to take mostly stock in MHAN for Debt that is worthless with out the merger!
That ask/bid spread the last few days was a real joke. Some body that sold at .025 earlier this week must be real pissed by now!
If the stock is worth .08, and all the warrants are converted at .08, the company swaps new shares for .08, when the existing shares are worth .08, where is the dilution? It improves the compnaies cash position and it future potential based on the improved cash.
The next question is what will the merger cost us!!!!! My guess is the merger will cost us about .01-.02 a share in real cost (stock dilution) wise for what we will get. I expect the creditors are going to take mostly stock in MHAN for Debt that is worthless with out the merger!
That ask/bid spread the last few days was a real joke. Some body that sold at .025 earlier this week must be real pissed by now!
Recent TGTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:33:42 PM
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 03/06/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 10:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:08:34 PM
- TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis • GlobeNewswire Inc. • 02/08/2026 09:17:55 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/06/2026 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 09:27:48 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones • GlobeNewswire Inc. • 01/13/2026 09:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:15:33 PM
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference • GlobeNewswire Inc. • 11/28/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 10:31:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/24/2025 09:04:15 PM
- TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit • GlobeNewswire Inc. • 11/10/2025 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2025 10:01:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:31:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 12:34:54 PM
